natgillin/translations-raw huggingface dataset:
Viruses isolated from patients on darunavir /ritonavir 600/100 mg twice daily experiencing virologic failure by rebound that were susceptible to tipranavir at baseline remained susceptible to tipranavir after treatment in the vast majority of cases. 
Izolirani virusi u bolesnika na darunaviru/ritonaviru od 600/100 mg dvaput na dan u kojih je došlo virološkog neuspjeha zbog ponovnog porasta virusa u krvi, bili su osjetljivi na tipranavir na početku liječenja u velikoj većini su slučajeva ostali osjetljivi na tipranavir i nakon liječenja.
Darunavir/ritonavir should be used during pregnancy only if the potential benefit justifies the potential risk. 
Darunavir/ritonavir se tijekom trudnoće smiju uzimati samo ako potencijalna korist opravdava potencijalni rizik.
Clinical monitoring is recommended when co-administering darunavir with low dose ritonavir with these antidepressants and a dose adjustment of the antidepressant may be needed. 
Preporučuje se kliničko praćanje kada se ti antidepresivi primjenjuju istodobno s darunavirom s niskom dozom ritonavira, a može biti potrebna prilagodba doze antidepresiva.
How to store Darunavir Krka 
Kako čuvati Darunavir Krka
A dose decrease may be needed for these drugs when co-administered with darunavir co-administered with low dose ritonavir. 
Može biti potrebno smanjenje doze za te lijekove kada se primjenjuju istodobno s darunavirom s istodobno primijenjenom niskom dozom ritonavira.
Dexamethasone (systemic) Not studied. 
Deksametazon (sistemski)
In addition, reactivation of herpes simplex and herpes zoster has been observed in clinical studies with darunavir co-administered with low dose ritonavir. 
Nadalje, u kliničkim ispitivanjima s darunavirom primijećena je reaktivacija herpesa simpleksa i herpesa zostera uz istodobno liječenje s niskom dozom ritonavira.
Each film-coated tablet contains 400 mg or 800 mg darunavir. 
Jedna filmom obložena tableta sadrži 400 mg ili 800 mg darunavira.
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that are highly dependent on CYP3A for clearance, which results in increased exposure to the coadministered medicinal product. 
Darunavir pojačan bilo ritonavirom bilo kobicistatom inhibira eliminaciju djelatnih tvari čiji klirens u velikoj mjeri ovisi o CYP3A, što dovodi do povećane izloženosti istodobno primijenjenom lijeku.
Darunavir may increase antifungal plasma concentrations and posaconazole, isavuconazole, itraconazole, or fluconazole may increase darunavir concentrations. 
Darunavir može povećati koncentracije antifungika u plazmi, a posakonazol, izavukonazol, itrakonazol ili flukonazol mogu povećati koncentracije darunavira. (CYP3A i/ili P-gp inhibicija)
ART-experienced paediatric patients (3 to 17 years of age and weighing at least 40 kg) 
Pedijatrijski bolesnici koji su prethodno liječeni ART-om (u dobi od 3 do 17 godina i težine najmanje 40 kg)
Caution should be exercised when combining one of these antineoplastic agents with darunavir with low dose ritonavir. 
Potreban je oprez kada se neki od tih antineoplastika kombinira s darunavirom s niskom dozom ritonavira.
Darunavir co-administered with low dose ritonavir must not be used concomitantly with products containing St John's wort (Hypericum perforatum) (see section 4.3). 
Darunavir istodobno primijenjen s niskom dozom ritonavira ne smije se istodobno primijenjivati s proizvodima koji sadržavaju gospinu travu (Hypericum perforatum) (vidjeti dio 4.3).
Boosted darunavir must not be used concomitantly with products containing St John's wort (Hypericum perforatum) (see section 4.3). 
Pojačan darunavir ne smije se istodobno primjenjivati s proizvodima koji sadržavaju gospinu travu (Hypericum perforatum) (vidjeti dio 4.3).
Darunavir Krka might increase the risk for elevated potassium levels by drospirenone. 
Darunavir Krka može povećati rizik od nastanka povišenih razina kalija radi drospirenona.
Twice daily dosing Weight 
Doziranje dvaput na dan
ANTICONVULSANTS Phenobarbital Phenytoin 
Fenobarbital Fenitoin
Concominant administration of boosted darunavir and lurasidone, pimozide or sertindole is contraindicated (see section 4.3). 
Istodobna primjena pojačanog darunavira i lurasidona, pimozida ili sertindola je kontraindicirana (vidjeti dio 4.3).
Alternative or additional contraceptive measures are recommended when oestrogen-based contraceptives are co-administered 
Preporučuju se druge ili zamjenske kontracepcijske mjere kada se kontraceptivi na bazi estrogena primjenjuju istodobno s pojačanim darunavirom.
Co-administration is expected to reduce plasma concentrations of darunavir, ritonavir and cobicistat, which could lead to loss of therapeutic effect and possible development of resistance (see sections 4.4 and 4.5). 
Očekuje se da će istodobna primjena sniziti koncentracije darunavira, ritonavira i kobicistata u plazmi, što može dovesti do gubitka terapijskog učinka i mogućeg razvoja rezistencije (vidjeti dijelove 4.4 i
Adverse reactions are listed by system organ class (SOC) and frequency category. 
Nuspojave su navedene prema klasifikaciji organskih sustava i kategoriji učestalosti.
The recommended dose regimen is 800 mg once daily with ritonavir 100 mg once daily taken with food. 
Preporučeni režim doziranja je 800 mg jedanput na dan s ritonavirom od 100 mg jedanput na dan uzeto s hranom.
Darunavir Krka 400mg film-coated tabletsareavailable in bottlescontaining 30 film-coated tablets (1 bottleof 30 film-coated tablets), 60 film-coated tablets (2 bottlesof 30 film-coated tablets), 90 filmcoated tablets (3 bottlesof 30 film-coated tablets)and 180 film-coated tablets (6 bottlesof 30 filmcoated tablets)in a box. 
Darunavir Krka 400 mg filmom obložene tablete dostupne su u bočicama koje sadrže 30 filmom obloženih tableta (1 bočica s 30 filmom obloženih tableta), 60 filmom obloženih tableta (2 bočice s 30 filmom obloženih tableta), 90 filmom obloženih tableta (3 bočice s 30 filmom obloženih tableta) i 180 filmom obloženih tableta (6 bočica s 30 filmom obloženih tableta) u kutiji.
Voriconazole should not be combined with darunavir co-administered with low dose ritonavir unless an assessment of the benefit/risk ratio justifies the use of voriconazole. 
Vorikonazol se ne smije kombinirati s darunavirom istodobno primijenjenim s niskom dozom ritonavira, osim ako se procijeni da omjer koristi i rizika opravdava primjenu vorikonazola.
Systemic dexamethasone should be used with caution when combined with darunavir co-administered with low dose ritonavir. 
Sistemski deksametazon mora se primijeniti s oprezom kada se kombinira s darunavirom primijenjenim istodobno s niskom dozom ritonavira.
Co-administration of darunavir and ritonavir with other medicinal products that inhibit CYP3A may decrease the clearance of darunavir and ritonavir, which may result in increased plasma concentrations of darunavir and ritonavir. 
Istodobna primjena darunavira i ritonavira s drugim lijekovima koji inhibraju CYP3A može smanjiti klirens darunavira i ritonavira i tako dovesti do povišenja koncentracija darunavira i ritonavira u plazmi.
Atorvastatin 10 mg once daily atorvastatin AUC ↑ 3-4 fold atorvastatin Cmin ↑ ≈5.5-10 fold atorvastatin Cmax ↑ ≈2 fold darunavir/ritonavir 
Atorvastatin 10 mg jedanput na dan atorvastatin AUC ↑ 3-4 puta atorvastatin Cmin ↑ ≈5.5-10 puta atorvastatin Cmax ↑ ≈2 puta
Co-administration of darunavir and ritonavir with medicinal products which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result in increased plasma concentrations of these medicinal products, which could increase or prolong their therapeutic effect and adverse reactions. 
Istodobna primjena darunavira i ritonavira s lijekovima koji se primarno metaboliziraju putem CYP2D6 (poput flekainida, propafenona, metoprolola) može rezultirati povišenjem plazmatskih koncentracija tih lijekova, što može povećati ili produljiti njihov terapijski učinak i nuspojave.
(induction of CYP450 enzymes) Concentrations of voriconazole may increase or decrease when co-administered with darunavir co-administered with 
Ritonavir može sniziti koncentracije vorikonazola u plazmi. (indukcija CYP450 enzima) Koncentracije vorikonazola mogu se povećati ili smanjiti kada se istodobno primijenjuje s darunavirom istodobno primijenjenim s kobicistatom. (inhibicija CYP450 enzima)
Co-administration of darunavir/ritonavir with medicinal products primarily metabolised by CYP3A and/or CYP2D6 or transported by P-gp may result in increased systemic exposure to such medicinal products, which could increase or prolong their therapeutic effect and adverse reactions. 
Istodobna primjena darunavira/ritonavira s lijekovima koji se primarno metaboliziraju putem CYP3A i/ili CYP2D6 ili prenose putem P-gp-a može rezultirati povećanom sistemskom izloženošću tim lijekovima, što može povećati ili produljiti njihov terapijski učinak i nuspojave.
Indinavir 800 mg twice daily indinavir AUC ↑ 23% indinavir Cmin ↑ 125% indinavir Cmax ↔ darunavir AUC ↑ 24% darunavir Cmin ↑ 44% darunavir Cmax ↑ 11% Indinavir: comparison of indinavir/ritonavir 800/100 mg twice daily 
Indinavir 800 mg dvaput na dan indinavir AUC ↑ 23% indinavir Cmin ↑ 125% indinavir Cmax ↔ darunavir AUC ↑ 24% darunavir Cmin ↑ 44% darunavir Cmax ↑ 11% Indinavir: usporedba indinavira/ritonavira 800/100 mg dvaput na dan naspram indinavira/darunavira/ritonavira 800/400/100 mg dvaput na dan.
Caution should be exercised when clarithromycin is combined with darunavir co-administered with low dose ritonavir. 
Nužan je oprez kada se klaritromicin kombinira s darunavirom primijenjenim istodobno s niskom dozom ritonavira.
Therefore, coadministration of boosted darunavir and sildenafil when used for the treatment of pulmonary arterial hypertension is contraindicated (see section 4.3). 
Stoga je istodobna primjena pojačanog darunavira i sildenafila kada se primjenjuje za liječenje plućne arterijske hipertenzije kontraindicirana (vidjeti dio 4.3).
For additional clinical study results in ART-experienced adults and paediatric patients, refer to the Summary of Product Characteristics for Darunavir Krka 600 mg tablets. 
Rezultate dodatnih kliničkih ispitivanja u odraslih i pedijatrijskih bolesnika prethodno liječenih ART-om, vidjeti u sažetku opisa svojstava lijeka za Darunavir Krka 600 mg tablete.
≥ 15 kg-< 30 kg 600 mg darunavir/100 mg ritonavir once daily 
≥ 15 kg-< 30 kg 600 mg darunavir/100 mg ritonavir jedanput na dan
When administered concomitantly with darunavir and low dose ritonavir, the patient's tolerability of bosentan should be monitored. 
Kada se bosentan daje istodobno s darunavirom i niskom dozom ritonavira, mora se pratiti bolesnikova podnošljivost bosentana.
At 48 weeks non-inferiority in virologic response to the darunavir/ritonavir treatment, defined as the percentage of patients with plasma HIV-1 RNA level < 400 and < 50 copies/ml, was demonstrated (at the pre-defined 12% non-inferiority margin) for both ITT and OP populations. 
U 48. tjednu, neinferiornost u virološkom odgovoru na liječenje darunavirom/ritonavirom, definiran kao postotak bolesnika s HIV-1 RNK razinom u plazmi < 400 i < 50 kopija/ml, pokazan je (uz prethodno definiranu 12% granicu neinferiornosti) za ITT i OP populaciju.
Renal and urinary disorders uncommon acute renal failure, renal failure, nephrolithiasis, increased blood creatinine, proteinuria, bilirubinuria, dysuria, nocturia, pollakiuria rare decreased creatinine renal clearance 
Poremećaji bubrega i mokraćnog sustava manje često akutno zatajenje bubrega, zatajenje bubrega, nefrolitijaza, povišen kreatinin u krvi, proteinurija, bilirubinurija, dizurija, nokturija, polakizurija rijetko snižen bubrežni klirens kreatinina
Exposure to these immunosuppressants will be increased when co-administered with darunavir coadministered with low dose ritonavir. 
Izloženost tim imunosupresivima bit će povećana ako se primjenjuju istodobno s darunavirom primijenjenim istodobno s niskom dozom ritonavira. (CYP3A inhibicija)
Bottle (HDPE), child resistant temper evident PP closure with a desiccant: - 30 tablets: 1 bottle of 30 film-coated tablets, - 90 tablets. 
Bočica (HDPE), PP zatvarač s evidencijom otvaranja siguran za djecu sa sredstvom za sušenje: - 30 tableta: 1 bočica s 30 filmom obloženih tableta, - 90 tableta: 3 bočice s 30 filmom obloženih tableta.
Concomitant administration of boosted darunavir with dabigatran or ticagrelor is contraindicated (see section 4.3). 
Istodobna primjena pojačanog darunavira s dabigatranom ili tikagrelorom je kontraindicirana (vidjeti dio 4.3).
Postpartum (6-12 weeks) (n=16) 
Postpartalno razdoblje (6-12 tjedana) (n=16)
The recommended dose of emtricitabine/tenofovir alafenamide is 200/10 mg once daily when used with boosted darunavir. 
Preporučena doza emtricitabina/tenofoviralafenamida kada se uzima s pojačanim darunavirom je 200/10 mg jedanput na dan.
For clinical trial results in ART-naïve paediatric patients aged 12 to 17 years, refer to the Summary of Product Characteristics for Darunavir Krka 400 mg and 800 mg tablets. 
Rezultate kliničkih ispitivanja u pedijatrijskih bolesnika koji nisu liječeni ART-om u dobi od 12 do 17 godina, pogledajte u sažetku opisa svojstava lijeka za lijek Darunavir Krka 400 mg i 800 mg tablete.
600 mg darunavir /100 mg ritonavir twice daily with ritonavir oral solution: 80 mg/ml 
600 mg darunavir /100 mg ritonavir dvaput na dan s oralnom otopinom ritonavira: 80 mg/ml
Buprenorphine/naloxone 8/2 mg-16/4 mg once daily buprenorphine AUC ↓ 11% buprenorphine Cmin ↔ buprenorphine Cmax ↓ 8% norbuprenorphine AUC ↑ 46% norbuprenorphine Cmin ↑ 71% norbuprenorphine Cmax ↑ 36% naloxone AUC ↔ naloxone Cmin ND naloxone Cmax ↔ 
Buprenorfin/nalokson 8/2 mg-16/4 mg jedanput na dan buprenorfin AUC ↓ 11% buprenorfin Cmin ↔ buprenorfin Cmax ↓ 8% norbuprenorfin AUC ↑ 46% norbuprenorfin Cmin ↑ 71% norbuprenorfin Cmax ↑ 36% nalokson AUC ↔ nalokson Cmin ND nalokson Cmax ↔
Gastrointestinal disorders very common diarrhoea common vomiting, nausea, abdominal pain, increased blood amylase, dyspepsia, abdominal distension, flatulence uncommon pancreatitis, gastritis, gastrooesophageal reflux disease, aphthous stomatitis, retching, dry mouth, abdominal discomfort, constipation, increased lipase, eructation, oral dysaesthesia rare stomatitis, haematemesis, cheilitis, dry lip, coated tongue 
Poremećaji probavnog sustava vrlo često proljev često povraćanje, mučnina, bol u abdomenu, povišene amilaze u krvi, dispepsija, distenzija abdomena, flatulencija manje često pankreatitis, gastritis, gastroezofagealna refluksna bolest, aftozni stomatitis, dizanje želuca, suha usta, nelagoda u abdomenu, konstipacija, povišena lipaza, podrigivanje, oralna dizestezija rijetko stomatitis, hematemeza, heilitis, suhe usne, obložen jezik
It is recommended that the international normalised ratio (INR) be monitored when warfarin is combined with darunavir coadministered with low dose ritonavir. 
Preporučuje se praćenje protrombinskog vremena (INR, od engl. international normalised ratio) kada se varfarin primjenjuje u kombinaciji s darunavirom primijenjenog istodobno s niskom dozom ritonavira.
Viruses selected in these conditions and showing decreased susceptibility to darunavir (range: 23-50fold) harboured 2 to 4 amino acid substitutions in the protease gene. 
Odabrani virusi nisu mogli rasti u prisutnosti darunavira u koncentracijama iznad 400 nM. Virusi odabrani u tim uvjetima, koji su pokazivali smanjenu osjetljivost na darunavir (raspon: 23-50 puta) pohranili su 2 do 4 aminokiselinskih supstitucija u genu proteaze.
The usual dose of Darunavir Krka is 800 milligram (2 tablets containing 400 milligram of Darunavir Krka or 1 tablet containing 800 milligram of Darunavir Krka) once daily. 
Uobičajena doza lijeka Darunavir Krka je 800 miligrama (2 tablete koje sadrže 400 miligrama lijeka Darunavir Krka ili 1 tableta koja sadrži 800 miligrama lijeka Darunavir Krka) jedanput na dan.
OESTROGEN-BASED CONTRACEPTIVES Drospirenone 
NA BAZI ESTROGENA
Concomitant use of salmeterol and boosted darunavir may increase plasma concentrations of salmeterol. 
Istodobna primjena salmeterola i pojačanog darunavira može povećati koncentracije salmeterola u plazmi.
Renal impairment No dose adjustment is required in patients with renal impairment (see sections 4.4 and 5.2). 
U bolesnika s oštećenjem funkcije bubrega nije potrebna prilagodba doze (vidjeti dijelove 4.4 i 5.2).
Darunavir Krka 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (ART)-naïve (see section 4.2). 
Darunavir Krka od 400 mg i 800 mg tablete mogu se primjenjivati da bi se osigurali prikladni režimi doziranja za liječenje HIV-1 infekcije u odraslih i pedijatrijskih bolesnika od 3 godine starosti i tjelesne težine barem 40 kg koji: - nisu prethodno liječeni antiretrovirusnom terapijom (ART) (vidjeti dio 4.2). - su prethodno liječeni ART-om, koji nemaju mutacije povezane s rezistencijom na darunavir (DRV-RAM) i koji imaju plazmatsku koncentraciju HIV-1 RNK
in certain patients who have used antiretroviral medicines before (your doctor will determine this). 
Doza za odrasle koji su već prije uzimali antiretrovirusne lijekove (to će odrediti Vaš liječnik)
Metabolism and nutrition disorders common diabetes mellitus, hypertriglyceridaemia, hypercholesterolaemia, hyperlipidaemia uncommon gout, anorexia, decreased appetite, decreased weight, increased weight, hyperglycaemia, insulin resistance, decreased high density lipoprotein, increased appetite, polydipsia, increased blood lactate dehydrogenase 
Poremećaji metabolizma i prehrane često dijabetes melitus, hipertrigliceridemija, hiperkolesterolemija, hiperlipidemija manje često giht, anoreksija, smanjen apetit, smanjena tjelesna težina, povećana tjelesna težina, hiperglikemija, rezistencija na inzulin, sniženi lipoproteini visoke gustoće, povećan apetit, polidipsija, povišena laktat dehidrogenaza u krvi
Clinical monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with darunavir with low dose ritonavir. 
Preporučeno je kliničko praćenje terapijskih učinaka i nuspojava kada se ovi lijekovi primjenjuju istodobno s pojačanim darunavirom.
ANTIGOUT MEDICINES Colchicine 
LIJEKOVI ZA LIJEČENJE GIHTA Kolhicin
12 ART-naïve HIV-1 infected paediatric patients aged from 12 to 17 years and weighing at least 40 kg who received darunavir tablets with low dose ritonavir once daily in combination with other antiretroviral agents (see section 5.1). 
- 12 pedijatrijskih bolesnika u dobi od 12 do 17godina i težine najmanje 40kg, koji nisu prethodno liječeni ART-om, a inficirani su virusom HIV-1 te su primali darunavir tablete s niskom dozom ritonavira jedanput na dan u kombinaciji s drugim antiretrovirusnim lijekovima (vidjeti dio 5.1).
Recommendations concerning coadministration 
Preporuke vezane uz istodobnu primjenu
Bottle (HDPE), child resistant temper evident PP closure with a desiccant: - 30 tablets: 1 bottle of 30 film-coated tablets, - 60 tablets: 2 bottles of 30 film-coated tablets, - 90 tablets: 3 bottles of 30 film-coated tablets, - 180 tablets: 6 bottles of 30 film-coated tablets. 
Bočica (HDPE), PP zatvarač s evidencijom otvaranja siguran za djecu sa sredstvom za sušenje: - 30 tableta: 1 bočica s 30 filmom obloženih tableta, - 60 tableta: 2 bočice s 30 filmom obloženih tableta, - 90 tableta: 3 bočice s 30 filmom obloženih tableta, - 180 tableta: 6 bočica s 30 filmom obloženih tableta.
Human experience of acute overdose with darunavir co-administered with low dose ritonavir is limited. 
Iskustvo akutnog predoziranja u ljudi darunavirom primijenjenim istodobno s niskom dozom ritonavira je ograničeno.
Human experience of acute overdose with darunavir co-administered with cobicistat or low dose ritonavir is limited. 
Iskustvo akutnog predoziranja u ljudi darunavirom primijenjenim istodobno s kobicistatom ili niskom dozom ritonavira je ograničeno.
How to take Darunavir Krka 
Kako uzimati Darunavir Krka
The interaction profile of darunavir may differ depending on whether ritonavir or cobicistat is used as pharmacoenhancer. 
Profil interakcija darunavira može se razlikovati ovisno o tome je li kao farmakokinetički pojačivač korišten ritonavir ili kobicistat.
In women receiving darunavir/ritonavir 600/100 mg twice daily during the second trimester of pregnancy, mean intra-individual values for total darunavir Cmax, AUC12h and Cmin were 28%, 26% and 26% lower, respectively, as compared with postpartum; during the third trimester of pregnancy, total darunavir Cmax, AUC12h and Cmin values were 18%, 16% lower and 2% higher, respectively, as compared with postpartum. 
U žena koje su primale darunavir/ritonavir 600/100 mg dva puta na dan tijekom drugog tromjesečja trudnoće, srednje intra-individualne vrijednosti za ukupni darunavir Cmax, AUC12h i Cmin bile su 28%, 26% odnosno 26% niže, uspoređujući s postpartalnim razdobljem; tijekom trećeg tromjesečja trudnoće, vrijednosti za ukupni darunavir Cmax, AUC12h i Cmin bile su 18%, 16% niže, odnosno 2% više, uspoređujući s postpartalnim razdobljem.
Concominant use of everolimus or irinotecan and boosted darunavir is not recommended. 
Istodobno uzimanje everolimusa ili irinotekana i pojačanog darunavira se ne preporučuje.
Darunavir Krkacannot work properly without food. 
Darunavir Krka ne može pravilno djelovati bez hrane.
Darunavir Krka 800 mg film-coated tablets (tablets): 
Darunavir Krka 800 mg filmom obložene tablete (tablete):
Darunavir binds predominantly to 1-acid glycoprotein. 
Darunavir se pretežno veže na 1-kiseli glikoprotein.
(CYP3A and OATP1B inhibition) 
izloženost grazopreviru. (CYP3A i OATP1B inhibicija)
For patients with renal or hepatic impairment colchicine with darunavir co-administered with low dose ritonavir is contraindicated (see sections 4.3 and 4.4). 
Za bolesnike s oštećenjem bubrega ili jetre kolhicin s darunavirom primijenjenim istodobno s niskom dozom ritonavira je kontraindiciran (vidjeti dijelove 4.3 i 4.4).
Take Darunavir Krka always together with 100 milligram of ritonavir. 
- Lijek Darunavir Krka uvijek uzimajte zajedno sa 100 miligrama ritonavira.
In most cases, Darunavir Krka can be combined with anti-HIV medicines belonging to another class [e.g. NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase inhibitors), CCR5 antagonists and FIs (fusion inhibitors)]. 
NRTI (nukleozidni inhibitori reverzne transkriptaze), NNRTI (ne-nukleozidni inhibitori reverzne transkriptaze), antagonisti receptora CCR5 i IF (inhibitori fuzije)].
Co-administration of darunavir coadministered with cobicistat and rifabutin is not recommended. 
Primjena darunavira istodobno primijenjenog s kobicistatom i rifabutinom se ne preporučuje.
30 film-coated tablets: EU/1/17/1249/009 90 film-coated tablets: EU/1/17/1249/010 
30 filmom obloženih tableta: EU/1/17/1249/009 90 filmom obloženih tableta: EU/1/17/1249/010
Boosted darunavir can be coadministered with proton pump inhibitors without dose adjustments. 
Pojačan darunavir može biti primijenjen istodobno s inhibitorima protonske pumpe bez prilagodbe doze.
Vascular disorders uncommon hypertension, flushing 
Krvožilni poremećaji manje često hipertenzija, navale vućine
If efavirenz is to be used in combination with darunavir, the darunavir/ritonavir 600/100 mg twice daily regimen should be used. 
Ako je potrebno primjenjivati efavirenz u kombinaciji s darunavirom, za darunavir/ritonavir se mora primijeniti režim od 600/100 mg dvaput na dan.
EU/1/17/1249/009 30 film-coated tablets EU/1/17/1249/010 90 film-coated tablets 
EU/1/17/1249/009 30 filmom obloženih tableta EU/1/17/1249/010 90 filmom obloženih tableta
Medicinal products that may be affected by darunavir boosted with cobicistat 
Lijekovi na koje može utjecati darunavir pojačan s kobicistatom